Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stanislaw Chorzepa

Internal Medicine Kensington, CT Doctor of Osteopathy

NPI 1750375127 CMS profile 261471

211 New Britain Rd, Suite 103, Kensington, CT 06037

Open in the dashboard

General payments

$5,474

326 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stanislaw Chorzepa of Kensington, CT is reported in the CMS Open Payments database as having received $5,474 across 326 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $726 36
2024 General $827 39
2023 General $835 49
2022 General $869 53
2021 General $1,115 73
2020 General $550 38
2019 General $552 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stanislaw Chorzepa
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Stanislaw Chorzepa were reported at $726. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Stanislaw Chorzepa Internal Medicine median Middle half National median
2019 $552 $159 $48–$570 $163
2020 $550 $119 $33–$402 $114
2021 $1,115 $135 $37–$521 $132
2022 $869 $141 $42–$496 $149
2023 $835 $149 $45–$519 $160
2024 $827 $154 $47–$537 $164
2025 $726 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,089 66 payments
  2. AstraZeneca Pharmaceuticals LP $883 57 payments
  3. Pfizer Inc. $514 31 payments
  4. Lilly USA, LLC $484 27 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $419 23 payments
  6. Novo Nordisk Inc $336 21 payments
  7. Janssen Pharmaceuticals, Inc $172 11 payments
  8. Phathom Pharmaceuticals, Inc. $162 10 payments
  9. Sanofi-Aventis U.S. LLC $148 10 payments
  10. Esperion Therapeutics, Inc. $137 2 payments
  11. Other $1,131 68 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,463 325 payments
  2. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. VRAYLAR $809 51 payments
  2. FARXIGA $540 37 payments
  3. ELIQUIS $279 19 payments
  4. BREZTRI $262 15 payments
  5. JARDIANCE Diabetes $248 13 payments
  6. JARDIANCE Diabetes $219 13 payments
  7. JARDIANCE Diabetes $187 9 payments
  8. MOUNJARO $181 10 payments
  9. TRULICITY $175 10 payments
  10. Ozempic $154 10 payments
  11. Other $4,166 238 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 100 drugs

Part D claims

5,622

Median for Osteopathic Manipulative Medicine: 311

Drug cost

$679,463

Median for Osteopathic Manipulative Medicine: $11,323

Branded share of claims

24.6%

Median for Osteopathic Manipulative Medicine: 19.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 152 $196,002
Mounjaro Tirzepatide Brand 64 $76,604
Jardiance Empagliflozin Brand 62 $72,473
Eliquis Apixaban Brand 43 $56,971
Farxiga Dapagliflozin Propanediol Brand 35 $50,981
Glyxambi Empagliflozin/Linagliptin Brand 33 $31,682
Januvia Sitagliptin Phosphate Brand 20 $31,519
Linzess Linaclotide Brand 22 $30,378
Xarelto Rivaroxaban Brand 17 $29,038
Myrbetriq Mirabegron Brand 16 $12,217

The 10 drugs with the highest cost, of 100 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 526 Part D prescribers listed as Osteopathic Manipulative Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$37,517

Medicare's payments for the services billed

Medicare patients

120

Average age 72

Services billed

445

58 women, 62 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 33%
Diabetes 25%
Depression 24%
Ischemic heart disease 22%
Chronic kidney disease 22%
Atrial fibrillation 19%
Osteoporosis 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $106
  • Lilly USA, LLC $69
$175 62 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $93
$93 — —
NEXLETOL
  • Esperion Therapeutics, Inc. $79
$79 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $78
$78 — —
VRAYLAR
  • AbbVie, Inc. $76
$76 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

326 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record